Dr. Mary Claire Haver

They didn't de-aggregate the male versus female data.

Women have cardiovascular disease differently than men.

Men tend to have their heart attacks, their clogged vessels way high up, you know, in the very larger arteries as they exit the, go right into the heart muscle.

They have these bigger blockages higher up.

Women tend to have more diffuse microvascular disease in

It's going to present differently.

It's going to respond differently to these standard medications that were really tested in mostly men.

So we have a male bias.

Metabolic research rarely includes menopause.

You know why?

It's hard.

Even in the animals, we don't have a perimenopause model in rats, which is kind of the standard thing we test in, right?

If they want to use a menopause model, they take out the ovaries.

There's no transition.

So we don't know how these medications are going to affect when we're looking at preclinical data, preclinical meaning animal studies.

When we say that, that's what we mean.

We have a very long way to go.

Doctors are taught to focus.

I was taught, I was taught to focus on hot flashes, on vasomotor symptoms, not the cardiometabolic red flags.

We have to educate all of our clinicians.